Cannabidiol prevents mucosal HIV-1 transmission by targeting Langerhans cells, dendritic cells, macrophages and T-cells
T-cells infection. Altogether, CBD inhibits infection of all HIV-1 cellular targets, and commercial CBD products might be repositioned as novel HIV-1 pre-exposure prophylaxis, namely 'CBD PrEP'.
Authors
- Yonatan Ganor (ORCID: https://orcid.org/0000-0003-4430-7744)
- Morgane Bomsel (ORCID: https://orcid.org/0000-0002-9577-7474)
- Marc Zerbib
- Daniela Cota (ORCID: https://orcid.org/0000-0002-6909-2156)
- Jammy Mariotton
- Nicolas Barry Delongchamps (ORCID: https://orcid.org/0000-0001-5827-9567)
- Hugo Génin
- I. Matias
- Caio César Barbosa Bomfim
Institutions
- Centre National de la Recherche Scientifique (FR)
- Université de Bordeaux (FR)
- Inserm (FR)
- Université Paris Cité (FR)
- Neurocentre Magendie (FR)
- Institut Cochin (FR)
- Hôpital Saint-Vincent-de-Paul (FR)
Publication Details
- Journal
- Mucosal Immunology
- Published
- 2026-04-01
- DOI
- https://doi.org/10.1016/j.mucimm.2026.03.006
- Primary Topic
- Cannabis and Cannabinoid Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Sidaction
- Institut National de la Santé et de la Recherche Médicale
- Université de Bordeaux